l-Carnitine status in end-stage renal disease patients on automated peritoneal dialysis

Journal of Nephrology

Volumn 27, Issue 6, 2014, Pages 699-706

  Di Liberato, Lorenzo ^a   Arduini, Arduino ^b   Rossi, Claudia ^a   Di Castelnuovo, Augusto ^c   Posari, Cosima ^a   Sacchetta, Paolo ^a   Urbani, Andrea ^d,e   Bonomini, Mario ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CoreQuest Sagl ^*  (Switzerland)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

APD; CAPD; Carnitine species; End stage renal disease; l carnitine

Indexed keywords

ACYLCARNITINE; CARNITINE; BIOLOGICAL MARKER; DIALYSIS FLUID;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; END STAGE RENAL DISEASE; FEMALE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PERITONEAL DIALYSIS; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; QUADRUPOLE MASS SPECTROMETRY; ULTRAFILTRATION; ADVERSE EFFECTS; AGED; AUTOMATION; BLOOD; CASE CONTROL STUDY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEASIBILITY STUDY; HEALTH STATUS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; TANDEM MASS SPECTROMETRY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOMATION; BIOMARKERS; CARNITINE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DIALYSIS SOLUTIONS; FEASIBILITY STUDIES; FEMALE; HEALTH STATUS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912028187     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0076-x     Document Type: Article

References (32)

1. Bremer J (1983) Carnitine-metabolism and function. Physiol Rev 63:1420–1480
2. Zammit VA, Ramsay RR, Bonomini M, Arduini A (2009) Carnitine mitochondrial function and therapy. Adv Drug Deliv Rev 61:1353–1362
3. Guarnieri G, Situlin R, Biolo G (2001) Carnitine metabolism in uremia. Am J Kidney Dis 38:S63–S67
4. Eknoyan G, Latos DL, Lindberg J (2003) Practice recommendations for the use of l-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 41:868–876
5. Wanner C, Forstner-Wanner S, Schaeffer G, Schollmeyer P, Horl WH (1986) Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis. Am J Nephrol 6:206–211
6. Pliakogiannis T, Chatzidimitriou C, Evangeliou A, Böhles HJ, Kalaitzidis K (1993) Serum carnitine levels, lipid profile, and metabolic status of patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13(Suppl 2):S440–S443
7. Chatzidimitriou C, Plikogiannis T, Evangeliou A, Tsalkidou T, Böhles HJ, Kalaitzidis K (1993) Evaluation of carnitine levels according to the peritoneal equilibration test in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13(Suppl 2):S444–S447
8. Constantin-Teodosiu D, Kirby DP, Short AH, Burden RP, Morgan AG, Greenhaff PL (1996) Free and esterified carnitine in continuous ambulatory peritoneal dialysis patients. Kidney Int 49:158–162
9. Gzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A (1999) Continuous laboratory peritoneal dialysis (CAPD) adequacy influences serum free carnitine level. Int Urol Nephrol 31:533–540
10. Warady BA, Borum P, Stall C, Millspaugh J, Taggart E, Lum G (1990) Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 10:109–114
11. Kosan C, Sever L, Arisoy N, Caliskan S, Kasapcopur Ö (2003) Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr Nephrol 18:1184–1188
12. Marin VB, Azocar M, Molina M, Guerrero JL, Ratner R, Cano F (2006) Total carnitine and acylated carnitine ratio: relationship of free carnitine with lipid parameters in pediatric dialysis patients. Adv Perit Dial 22:130–135
13. Aguilar-Kitsu A, Ibarra-Cazares P, Mendoza-Guevara L et al (2006) Frequency of low carnitine levels in children on dialysis. Adv Perit Dial 22:208–210
14. Verrina E, Caruso U, Calevo MG et al (2007) Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol 22:727–733
15. Centers of Medicare & Medicaid Services (2002) Levocarnitine for use in the treatment of carnitine deficiency in ESRD patients. Transmittal AB-02-165. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Baltimore.
16. Michels WM, Verduijn M, Parikova A et al (2012) Time course of peritoneal function in automated and continuous peritoneal dialysis. Perit Dial Int 32:605–611
17. Chaundary K, Khanna R (2010) Biocompatible peritoneal dialysis solutions: do we have one? Clin J Am Soc Nephrol 5:723–732
18. Holmes CJ (2007) Glucotoxicity in peritoneal dialysis—solutions for the solution. Adv Chronic Kidney Dis 14:269–278
19. Bonomini M, Pandolfi A, Di Liberato L et al (2011) l-Carnitine is an osmotic agent suitable for peritoneal dialysis. Kidney Int 80:645–654
20. Bonomini M, Di Liberato L, Del Rosso G et al (2013) Effect of an l-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial. Am J Kidney Dis 62:929–938
21. Sun D, Cree MG, Zhang X, Boersheim E, Wolfe RR (2006) Measurement of stable isotopic enrichment and concentration of long-chain acyl-carnitines in tissue by HPLC-MS. J Lipid Res 47:431–439
22. Sirolli V, Rossi C, Di Castelnuovo A et al (2012) Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint. Blood Transfus 10(Suppl. 2):s78–s88
23. Csiky B, Bene J, Wittmann I, Sulyok E, Melegh B (2012) Effect of hemodialysis session on the dynamics of carnitine ester profile changes in l-carnitine pretreated end-stage renal disease patients. Int Urol Nephrol 45:847–855
24. Wajner M, Goodman SI (2011) Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies. J Bioenerg Biomembr 43:31–38
25. Hennermann JB, Roloff S, Gellermann J, Grüters A, Klein J (2009) False-positive newborn screening mimicking glutaric aciduria type I in infants with renal insufficiency. J Inherit Metab Dis 32(Suppl 1):S355–S359
26. Goek ON, Döring A, Gieger C et al (2012) Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 60:197–206
27. Gaggiotti E, Arduini A, Bonomini M et al (2005) Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits). Int J Artif Organs 28:177–187
28. Ramsay RR, Arduini A (1993) The carnitine acyltransferases and their role in modulating acyl-CoA pools. Arch Biochem Biophys 302:307–314
29. Ramsay RR, Zammit V (2004) Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med 25:475–493
30. Brass EP, Adler S, Sietsema KE et al (2001) Intravenous l-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 37:1018–1028
31. Arduini A, Bonomini M, Savica V, Amato A, Zammit V (2008) Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 120:149–156
32. Hamilton JJ, Hahn P (1987) Carnitine and carnitine esters in rat bile and human duodenal fluid. Can J Physiol Pharmacol 65:1816–1820